| BID | 16.60 | ASK | 25.00 | ||
| Open | 20.42 | Previous Close | 20.51 | ||
| Pre-Market | - | After-Market | 20.72 | ||
| - - | - -% |
| Target Price | 14.35 | Analyst Rating | Hold 2.67 | |
| Potential % | -30.74 | Finscreener Ranking | ★+ 43.19 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 51.30 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 38.77 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | ★★★+ 48.03 | |
| Price Range Ratio 52W % | 43.72 | Earnings Rating | Sell | |
| Market Cap | 12.16B | Earnings Date | 2nd Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.10 | |
| Beta | 1.04 |
Today's Price Range 20.4220.76 | 52W Range 15.2927.72 | 5 Year PE Ratio Range 8.5023.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.19% | ||
| 1 Month | 22.81% | ||
| 3 Months | -13.75% | ||
| 6 Months | -4.74% | ||
| 1 Year | 28.35% | ||
| 3 Years | -51.98% | ||
| 5 Years | -49.68% | ||
| 10 Years | -40.07% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 5.96 | |||
ROE last 12 Months | 5.32 | |||
ROA (5Y Avg) | 2.00 | |||
ROA last 12 Months | 2.00 | |||
ROC (5Y Avg) | 6.92 | |||
ROC last 12 Months | 3.60 | |||
Return on invested Capital Q | 1.01 | |||
Return on invested Capital Y | 1.09 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 3.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.20 | ||||
| 0.60 | ||||
| 0.65 | ||||
| 4.10 | ||||
| 13.40 | ||||
| 3.82 | ||||
| -2.48 | ||||
| 26.99 | ||||
| 23.53B | ||||
| Forward PE | 12.54 | |||
| PEG | 0.93 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.30 | ||||
| 0.45 | ||||
| 0.92 | ||||
| 4.70 | ||||
| Leverage Ratio | 2.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 27.70 | ||||
| 8.80 | ||||
| 18.20 | ||||
| 11.50 | ||||
| 4.87 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.46B | ||||
| 26.34 | ||||
| 1.58 | ||||
| 0.18 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.15 | ||||
| 0.71 | ||||
| 8.60 | ||||
| 11.43 | ||||
| Payout ratio | 31.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | 0.37 | 0.31 | -16.22 |
| Q02 2023 | 0.24 | 0.32 | 33.33 |
| Q01 2023 | 0.18 | 0.28 | 55.56 |
| Q04 2022 | 0.22 | 0.44 | 100.00 |
| Q03 2022 | 0.37 | 0.40 | 8.11 |
| Q02 2022 | 0.45 | 0.41 | -8.89 |
| Q01 2022 | 0.30 | 0.38 | 26.67 |
| Q04 2021 | 0.50 | 0.51 | 2.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | 0.36 | -7.69 | Negative |
| 12/2023 FY | 1.26 | -2.33 | Negative |
| 3/2024 QR | 0.31 | 29.17 | Positive |
| 12/2024 FY | 1.60 | 0.63 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | 0.37 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 233.89K |
| Shares Outstanding | 586.83K |
| Shares Float | 198.90M |
| Trades Count | 3.26K |
| Dollar Volume | 4.82M |
| Avg. Volume | 477.40K |
| Avg. Weekly Volume | 293.18K |
| Avg. Monthly Volume | 573.41K |
| Avg. Quarterly Volume | 565.62K |
Fresenius Medical Care AG (NYSE: FMS) stock closed at 20.51 per share at the end of the most recent trading day (a 0.2% change compared to the prior day closing price) with a volume of 249.05K shares and market capitalization of 12.16B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 125364 people. Fresenius Medical Care AG CEO is Rice Powell.
The one-year performance of Fresenius Medical Care AG stock is 28.35%, while year-to-date (YTD) performance is 25.52%. FMS stock has a five-year performance of -49.68%. Its 52-week range is between 15.285 and 27.715, which gives FMS stock a 52-week price range ratio of 43.72%
Fresenius Medical Care AG currently has a PE ratio of 12.20, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 0.65, a price to cashflow ratio of 4.10, a PEG ratio of 0.93, a ROA of 2.00%, a ROC of 3.60% and a ROE of 5.32%. The company’s profit margin is 4.87%, its EBITDA margin is 18.20%, and its revenue ttm is $15.46 Billion , which makes it $26.34 revenue per share.
Of the last four earnings reports from Fresenius Medical Care AG, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.37 for the next earnings report. Fresenius Medical Care AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fresenius Medical Care AG is Hold (2.67), with a target price of $14.35, which is -30.74% compared to the current price. The earnings rating for Fresenius Medical Care AG stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fresenius Medical Care AG has a dividend yield of 4.15% with a dividend per share of $0.71 and a payout ratio of 31.00%.
Fresenius Medical Care AG has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.49, ATR14 : 0.41, CCI20 : 92.62, Chaikin Money Flow : 0.24, MACD : 0.57, Money Flow Index : 82.31, ROC : 19.31, RSI : 71.76, STOCH (14,3) : 96.18, STOCH RSI : 1.00, UO : 65.48, Williams %R : -3.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fresenius Medical Care AG in the last 12-months were:
Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
CEO: Rice Powell
Telephone: +49 61726082522
Address: Else-Kroener-Strasse 1, Bad Homburg 61352, , DE
Number of employees: 125 364
TipRanks News for FMS
Mon, 20 Nov 2023 07:10 GMT Analysts Conflicted on These Healthcare Names: Fresenius Medical Care (FMS), Solid Biosciences (SLDB) and Merck & Company (MRK)
- TipRanks. All rights reserved.
